Standard Specimen Reference Set: Lung

Abbreviated Name
LUNG REF
Lead Investigator
Bigbee, William L.University of Pittsburgh Cancer Institute
Coordinating Investigator
Feng, Ziding Fred Hutchinson Cancer Center
Involved Investigators

Abstact

The NCI/EDRN/SPORE Lung Cancer Biomarkers Group (LCBG) began its activities back in November 2004 and developed clear objectives and strategies on how to begin validating a series of candidate biomarkers for the early detection of lung cancer. The initial goal of the LCBG is to develop the requisite sample resources to validate serum/plasma biomarkers for the early diagnosis of lung cancer. Researchers may use these resources and process for continued biomarker refinement but this is not the primary activity of the LCBG.

Aims

Our specific goals include: 1.   Develop reference case/control serum/plasma sets held in a NCI repository and make these samples available to the research community. 2.   Define, refine and validate blood-based biomarkers for lung cancer. 3.   Test reproducibility of biomarkers within and across institutions. 4.   Test reproducibility of biomarkers within and across analytical platforms.

Analytic Method

N/A

Publications

  • No publications available at this time for this protocol.

Biomarkers

  • No biomarkers available at this time for this protocol.

Data Collections

  • No data collections available at this time for this protocol.
 Team Project
Start Date
Mar 18 2009
Estimated Finish Date
Mar 18 2010
Finish Date
Sep 30 2010
Protocol ID
115
Protocol Type
Reference Set
Field of Research
Other
Collaborative Group
Lung and Upper Aerodigestive Cancers Research Group
Cancer Types
  • Malignant neoplasm of bronchus and lung

Associated Forms